Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) FCF Margin (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of FCF Margin data on record, last reported at 4902.75% in Q3 2025.

  • For Q3 2025, FCF Margin fell 492632.0% year-over-year to 4902.75%; the TTM value through Sep 2025 reached 240.06%, down 5570.0%, while the annual FY2024 figure was 116.62%, 1122.0% up from the prior year.
  • FCF Margin reached 4902.75% in Q3 2025 per SGMO's latest filing, down from 98.46% in the prior quarter.
  • Across five years, FCF Margin topped out at 23.57% in Q3 2024 and bottomed at 10212.68% in Q1 2024.
  • Average FCF Margin over 5 years is 1617.9%, with a median of 219.32% recorded in 2022.
  • Peak YoY movement for FCF Margin: plummeted -1016425bps in 2024, then soared 980282bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 157.05% in 2021, then decreased by -19bps to 186.89% in 2022, then plummeted by -752bps to 1591.63% in 2023, then surged by 97bps to 53.89% in 2024, then plummeted by -8997bps to 4902.75% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 4902.75% in Q3 2025, 98.46% in Q2 2025, and 409.86% in Q1 2025.